Alto and Canopy Launch Native IRA Funding Integration for Private Market Investing

New integration gives issuers a more scalable way to tap retirement capital while simplifying IRA-funded investing

NASHVILLE, Tenn., Oct. 8, 2026 — Alto, the technology-led platform connecting retirement capital with private markets, today announced a new integration with Canopy, a modern platform that helps venture capital managers and issuers run SPVs with transparency and clarity. Building on the companies’ December 2025 partnership, the integration embeds Alto’s IRA funding infrastructure directly into Canopy’s investor onboarding, making it easier for issuers to accept retirement capital at scale while simplifying IRA-funded investing.

The integration makes funding a private market investment with an IRA more like funding one with cash. With a single authorization, required IRA information flows securely from Alto into Canopy, automatically populating subscription documents and streamlining custodial approval and investment funding. From initial investments through capital calls, increases, distributions, cancellations, and refunds, the integration keeps data synchronized across both platforms to support annual IRA reporting requirements and provide real-time visibility into investment status.

Turning IRA Capital Into a Growth Channel
IRA capital represents a significant opportunity for private market issuers, but accepting it has traditionally required additional steps that cash investments do not. From collecting IRA and custodian information to securing custodial approval and processing funds, those requirements can create added friction for issuers and investors alike, making retirement capital harder to incorporate into the fundraising process.

Removing most of those barriers creates another avenue for issuers to raise capital from both new and existing investors, including those who may be able to participate or increase their allocation by funding through an IRA. For investors, it means being able to put retirement assets to work without navigating a separate, manual process.

“Private market issuers shouldn’t have to choose between accessing retirement capital and keeping their fundraising process simple, yet that’s effectively been the tradeoff for too long,” said Eric Satz, Founder and CEO of Alto. “There’s an enormous pool of capital already sitting in IRAs, but the infrastructure hasn’t made it easy for issuers to access it. By integrating directly with Canopy, we’re changing that. Retirement dollars shouldn’t be a special case in private market fundraising. They should simply be another way investors fund the opportunities they believe in.”

The Retirement Opportunity 
The integration comes as demand for alternative investments continues to grow and more investors look beyond public markets to diversify their retirement portfolios. U.S. investors currently hold $19.9 trillion in IRAs, representing a significant pool of retirement capital that could be put to work in private markets. A PwC analysis found that even a modest 5% allocation to alternatives across 401(k)s and other tax-advantaged retirement vehicles could add over $1 trillion in new assets under management by 2030. Alto is seeing that opportunity translate into adoption, with Alto investors averaging 3.2 investments each and average investment size up 31.2% year over year.1

“For Canopy, this is about giving issuers more ways to raise capital without adding complexity to the fundraising experience,” said Jared Snow, CEO of Canopy. “Integrating Alto directly into our platform opens a long-term, tax-advantaged source of capital that has historically been more difficult to incorporate into private market fundraising. That’s a meaningful differentiator for Canopy and a better experience for the investors our customers serve.”

To learn more about how Alto and Canopy are streamlining IRA-funded investing together, visit grow.altoira.com/canopy.

About Alto
Alto is a technology-led self-directed IRA custodian and broker-dealer making it easier to invest retirement capital in private markets. As a qualified custodian and SEC-registered broker-dealer, Alto brings custody, compliance, investment execution, and technology together on one platform. Financial advisors execute private market deals inside client IRAs through Alto Private Deal Room, individual investors access curated alternatives through Alto Marketplace, and enterprise partners use Alto’s configurable, API-based infrastructure to embed retirement investing capabilities into their own platforms. Alto pairs AI-driven automation with deep alternatives expertise to streamline compliance, documentation, and execution workflows that have historically made private market retirement investing complex. Learn more at altoira.com.

DISCLAIMER: This communication is for informational purposes and does not constitute a solicitation of any securities. Private securities are intended for highly sophisticated investors. Private securities involve substantial risks, including loss of principal, lack of operating history, leverage, illiquidity, and concentration risk. Alto does not provide investment, legal, or tax advice. Investors should consult their own advisors and conduct due diligence before investing. Alto Solutions, Inc. is an administrator of IRAs and offers a platform to invest in private markets on its Private Deal Room. Alto Trust Co. is a state chartered trust company and passive custodian of IRAs. Alto Securities, LLC is a registered broker dealer, member of FINRA/SIPC and supports Alto Marketplace.

About Canopy
Canopy has built modern infrastructure to support how venture capital managers operate. Investors on Canopy’s platform can set up SPVs in minutes and manage capital, allocations, taxes, distributions, reporting, and LP communication in one platform. Thousands of investors and venture capital managers use Canopy to run SPVs, syndicates, and co-investment opportunities.. Learn more at www.heycanopy.com.

1 Alto internal data, as of September 30, 2026.

SOURCE Alto IRA

Stonefield Economics Deepens Texas Presence with VALUE Incorporated

Irving-based financial valuation and economic damages consulting firm becomes Stonefield’s third partner firm

DALLAS, Oct. 8, 2026 — Stonefield Economics (“Stonefield”), a national economic consulting and dispute advisory platform backed by Trinity Hunt Partners (“Trinity Hunt”), today announced that VALUE Incorporated (“VALUE”), an Irving, Texas-based financial valuation and economic damages consulting firm, has joined the platform. The partnership marks Stonefield’s third strategic acquisition, following its recent addition of Hancock Firm.

Founded in 2000, VALUE provides complex business valuation and broader economic damages consulting to law firms, corporations, and financial institutions across commercial litigation, family law, trust and estate matters, and intellectual property. The firm has built a deeply loyal client base by translating complex financial and valuation concepts into clear, credible guidance, the kind of rigor and dependability that has made VALUE a trusted, independent voice in the Dallas-Fort Worth market for more than two decades.

“VALUE has never had a strategy beyond taking care of every client, every time, and that’s exactly what drew us to Stonefield,” said David Fuller, Partner at VALUE Incorporated. “Joining a platform that shares that same commitment to clients and people gives our team the continuity to keep doing what we do best, backed by new infrastructure, resources, and leadership opportunities as the platform grows. It was the right next step, both for me personally and for VALUE, and it opens real opportunity for where we go from here.”

“David has built VALUE around something rare in this industry: the ability to simplify complex concepts for the clients who depend on that guidance,” said Gary Buckland, CEO of Stonefield Economics. “That kind of thought partnership and reliability is what earns client loyalty over decades, and it’s exactly the discipline we want at the center of Stonefield’s platform. We’re proud to welcome David and the whole VALUE team, and we’re excited to support them with the resources to keep building on the trust they’ve already earned in Texas.”

VALUE will continue serving its clients and employees the same way it always has, now backed by Stonefield’s shared resources. The partnership also brings new depth to the platform across commercial litigation, family law, and trust and estate consulting. Stonefield continues to pursue partnerships with strong firms across economic damages analysis, forensic accounting, and valuation services throughout North America. For more information, reach out to the Stonefield team directly at [email protected].

ABOUT VALUE INCORPORATED

VALUE Incorporated is a leading financial valuation and economic damages consulting firm specializing in the valuation of businesses, securities, and intellectual property as well as the calculation of economic loss. Founded in 2000, VALUE serves law firms, corporations, private equity firms, and fiduciaries across litigation, financial and tax reporting, and transaction advisory matters. The firm has built a strong network across Texas and is recognized for its independent thought partnership, accurate and rigorously supported opinions, and ability to clearly communicate complex issues. For more information, visit www.valueinc.com.

ABOUT STONEFIELD ECONOMICS

Stonefield Economics is an economic consulting and dispute advisory platform specializing in economic damages analysis, forensic accounting, and business valuation. Its family of companies provides sophisticated economic, statistical, and financial analysis to law firms, corporations, fiduciaries, private equity firms, and other organizations across litigation, regulatory, and transactional matters. Stonefield is building a national platform through organic growth and partnerships with leading specialized firms across North America. For more information, visit www.stonefieldeconomics.com.

ABOUT TRINITY HUNT PARTNERS

Trinity Hunt Partners is a growth-oriented private equity firm with over $2 billion of assets under management focused on building leading B2B and B2C services companies. Trinity Hunt’s mission is to provide the talent and strategic, operational, and financial capabilities needed to build entrepreneurial services companies into market leaders. Trinity Hunt was ranked tenth amongst all firms worldwide on HEC-Dow Jones’ most recent Top Small-Cap Buyout Firms List (2024), which ranks firms based on their performance for investors across funds raised over a 10-year period. For more information, visit www.trinityhunt.com.

MEDIA CONTACT

Priyanka Chodhari, Vice President of M&A

Stonefield Economics

[email protected] 

SOURCE Stonefield Economics

Vinci Pharmaceuticals Inc. Closes More Than $8 Million Series A Financing to Advance EPIPLANT™ Drug Delivery Platform

Key Takeaways

  • Combined with its Seed round of $8.5M, the company has raised more than $16.5M in support of its activities.
  • Vinci Pharmaceuticals closed an $8+ million Series A financing round to support manufacturing, testing/release activities and first-in-human studies of its EPIPLANT™ drug delivery platform.
  • EPIPLANT™, the company’s proprietary, episcleral sustained-release drug delivery platform is designed to address limitations of intraocular injections.
  • A Phase 1/2a clinical study is scheduled for 2027.

AVON-BY-THE-SEA, N.J., Oct. 8, 2026 /PRNewswire/ — Vinci Pharmaceuticals Inc., a specialty ophthalmic pharmaceutical company, has closed an $8+ million Series A financing round as the company advances development of its innovative EPIPLANT™ delivery platform. Previously, the company raised $8.5M, excluding interest on convertible notes, in Seed Stage financing, for a total of more than $16.5M.

Developed in the laboratory of Karl Csaky, MD, PhD, and licensed from the Retina Foundation of the Southwest in Dallas, Texas, EPIPLANT™ is a proprietary episcleral implant platform designed to provide sustained drug delivery to retinal tissues and address limitations associated with intraocular injections. Vinci is advancing the program with guidance from its scientific advisory board of physicians.

The financing was led by Dynagrow Capital, LLLP, with support from MintPharma Capital. Proceeds from the financing are expected to support GMP manufacturing, testing and release activities of the EPIPLANT™ VCI-002 product, and the Phase 1/2a study in 2027.

“We are grateful for the support and confidence of our investors and board, who recognize the potential of our EPIPLANT™ delivery system to transform the treatment of sight-threatening diseases and address unmet needs in the field,” said Philip A. Gioia, Co-founder, Chairman and Chief Executive Officer of Vinci Pharmaceuticals. “This financing supports an important next step: preparing for our first-in-human study. We believe EPIPLANT™ has the potential to provide safe sustained drug delivery to retinal tissues and reduce treatment burden for patients and physicians.”

Sarah Hassan, Managing Director at Dynagrow Capital added, “Vinci’s EPIPLANT represents a potential paradigm shift for eye doctors and their patients facing retinal disease challenges. This potential multi-molecule platform technology involving a needle-free delivery system for small molecules could dramatically increase adherence time for patients presently experiencing an unacceptably high dropout rate due to treatment burden. We are happy to partner with Vinci’s talented team and support them in this most pivotal time advancing EPIPLANTVCI-002 to patients.”

The company has been granted multiple patents covering its proprietary EPIPLANT™ technology and has completed preliminary preclinical testing. Vinci plans to initiate a first-in-human Phase 1/2a clinical study in 2027.

Existing drug delivery approaches for retinal diseases often require administration directly into the eye or face challenges in achieving effective drug concentrations in retinal tissues. EPIPLANT™ is designed to address these limitations through sustained drug delivery from an episcleral implant. The bioerodible platform is designed to accommodate a range of active pharmaceutical ingredients, with the potential to support multiple therapies for retinal diseases.

“EPIPLANT™ delivers targeted drug levels to the macula, making it a more desirable option for treating certain ophthalmic diseases of the retina compared to intravitreal injections, the current standard of care,” said Richard Lindstrom, MD, of Minnesota Eye Consultants. “The EPIPLANT™ technology also opens the door to novel therapies for retinal indications that are currently untreated.”

Vinci Pharmaceuticals plans one Phase 1/2a clinical trial of its EPIPLANT™ episcleral sustained-release delivery system in 2027. Currently the system can deliver small molecules, allowing for broad application for multiple retinal diseases.

About Vinci Pharmaceuticals
Vinci Pharmaceuticals Inc. is a clinic ready ophthalmic company that is leveraging a novel, proprietary platform to develop first-, best- and only-in-class products with differentiated profiles to treat certain diseases of the retina.

Safe Harbor
This press release contains forward-looking statements, which include information relating to future events, future financial performance, financial projections, strategies, expectations, competitive environment and regulations. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved.  Forward-looking statements are based on information Vinci Pharmaceuticals has when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.

Contact
Vinci Pharmaceuticals Inc.
Phil Gioia
Co-Founder, Chairman & CEO
Email: philip.gioia@vincipharmaceuticals.com

Vocca raises $20M after growing from 2,000 to 15,000 medical practitioners in a year

NEW YORK, Oct. 8, 2026 — Vocca announced a $20M Series A led by Norrsken VC, with participation from Heal Capital, Speedinvest and Firstminute Capital. Total funding is $25 million.

Vocca’s first product is an AI phone assistant that automates patient calls. A year ago, 2,000 medical practitioners used it. Today 15,000 do, across 1,500 practices and twenty specialties in the US and Europe. Over the same period, conversation volume grew 10x, to more than one million a month, and revenue grew 7x.

On average, Vocca resolves 70% of conversations end-to-end with no human involvement; its most mature customers exceed 85%. National groups run their scheduling on it, DAG Dental (37 practices) for instance, as do hospital systems such as the Hôpital Fondation de Rothschild, which handles intake, calls and confirmations with Vocca for its 350,000 yearly patients.

AI built for how medical practices actually work

Four in ten calls to a medical practice go unanswered, and nearly half of health workers report frequent burnout. Vocca learned each specialty’s scheduling logic, integrated with the software practices already use, and was built to handle patient data securely. Behind the voice is a scheduling engine with a library of specialty-specific models, so practices go live in days rather than months.

The second wave of healthcare AI is conversational

A quarter of US health spending still goes to administration, much of it on the phone. The first wave of AI in medicine was documentation; within a few years, ambient scribes became standard. The second wave is conversational, and it moves faster because it asks no one to change how they work: patients keep calling, staff keep their tools, and what changes is capacity.

Vocca will use the funding to build the best scheduling infrastructure in healthcare and the best interface for patients to reach it: new channels beyond voice, more specialties, and a deeper presence in the United States.

Find out more : https://vocca.com/en/resources/blog/vocca-raises-20m-series-a-led-by-norrsken-vc

About Vocca

Founded in July 2024 by Eliott Hoffenberg and Hugo Danet. Vocca employs around 40 people in New York and Paris and is hiring 40 more by the end of the year.

Press contact: [email protected]

About Norrsken VC

Norrsken VC is Europe’s leading early-stage impact fund, headquartered in Stockholm, with more than €500M under management and 60+ investments to date.

SOURCE Vocca

Thyme Companies Launches First New Venture, Thyme Therapeutics, To Build a More Sustainable, Lower-Cost Oncology Biosimilar Model

Thyme Therapeutics launches as a wave of major oncology biologics approaches loss of exclusivity, entering a market where pricing has remained unstable and volatile even as biosimilar competition has grown

NASHVILLE, Tenn., Oct. 8, 2026 — Thyme Companies, a family of businesses purpose-built to solve problems across the cancer care landscape, today announced the launch of Thyme Therapeutics, a new business focused on driving reductions in the cost of oncology drugs. The company will work closely with oncologists, health plans, and manufacturers to commercialize oncology biosimilars. Its model will help patients access more affordable care, make lower-cost treatments easier for oncologists to adopt, and reduce overall healthcare costs.

Biosimilars have already offered promising saving opportunities in cancer care, but unstable prices and other market dynamics have limited those savings. Even when lower-cost options are covered and prescribed, pricing can shift significantly from quarter to quarter, keeping drug spend high and unpredictable. Thyme Therapeutics is built to align incentives across manufacturers, payers, and providers so the savings from lower-cost biosimilars reach patients and hold up over time.

“Few challenges in oncology are more urgent to solve right now than the rising cost of cancer drugs,” said Robin Shah, executive chairman of Thyme Companies. “With Thyme Therapeutics, we have an opportunity to rethink how value moves through the system so that more of the savings created by biosimilars can ultimately benefit patients and the healthcare system as a whole.”

Thyme Therapeutics plans to launch its first asset in 2027 and is actively engaging leading oncology groups, biosimilar manufacturers, and health plans as it builds its initial portfolio. Thyme Therapeutics will build on Thyme Care’s mission to transform cancer care in a way that reduces costs for patients in partnership with both payers and providers as it works to bring additional biosimilars to market.

This launch comes at a critical inflection point for cancer care. U.S. oncology drug spending reached approximately $84 billion in 2025, an increase of roughly 20% in a single year, while several of the industry’s highest-cost cancer therapies are approaching loss of exclusivity. That opportunity could meaningfully reset the economics of cancer care, but only if lower-cost products achieve broad and sustained adoption. Thyme Therapeutics was built to help turn that opportunity into more predictable, durable savings.

Thyme Therapeutics is the first new business launched by Thyme Companies following its formation in September 2026, alongside its Series E financing, and will initially focus on biosimilar medications. Thyme Companies was established to build independent businesses that address distinct challenges across the cancer care ecosystem, with Thyme Therapeutics as the next such business alongside Thyme Companies’ first venture, Thyme Care. To learn more about the company and the team, visit thymetherapeutics.com.

About Thyme Companies
Thyme Companies is the parent of the Thyme family of businesses, focused on building companies against the disconnection in how cancer care is delivered, accessed and paid for. Anchored by Thyme Care, the nationally recognized oncology care company, Thyme Companies develops independent businesses connected by one mission: to transform the experience of cancer for the people living through it. To learn more, visit thymecompanies.com.

About Thyme Therapeutics
Thyme Therapeutics, part of the Thyme family of businesses, is building a new oncology biosimilars model designed to bring lower-cost medicines to market and reduce the cost of cancer via more stable, lower pricing. The company works with leading providers, manufacturers, and health plans to make lower-cost, clinically appropriate cancer treatments easier to adopt. To learn more, visit thymetherapeutics.com.

SOURCE Thyme Companies

Pivot Energy Closes $173 Million Term Loan Facility for 135 MWdc Distributed Solar Portfolio

DENVER, Oct. 8, 2026 — Pivot Energy, an impact-focused independent power producer of distributed-scale solar and energy storage, today announced the closing of a $173 million term loan facility for a portfolio of 51 community-scale solar projects totaling 135 Megawatts (MWdc) across six states.

Long-time financial partners First Citizens Bank (“First Citizens”), Huntington Bank, and BankUnited provided the takeout financing. The facility refinances the projects from Pivot’s construction warehouse and consolidates Pivot’s first three portfolios under a single term structure, marking the company’s first term loan financing. The transaction also frees up capacity in Pivot’s revolving construction facility to support continued construction of additional projects.

“Closing our first term loan across a consolidated portfolio is an important step for Pivot,” said Bret Labadie, Chief Financial Officer at Pivot Energy. “We’re grateful to First Citizens, Huntington, and BankUnited, who have supported Pivot from the start. This financing gives us the flexibility to grow faster and deliver lasting value where our projects are built, from community investment and agrivoltaics to local jobs and economic development. As the electricity landscape becomes more complex, we’re proud to work alongside utilities, corporate energy buyers, and ratepayers to deliver local, reliable power that strengthens the grid.”

“First Citizens is pleased to continue building on our long-standing relationship with Pivot Energy,” said Mike Lorusso, head of First Citizens Bank’s Energy Finance business. “This financing reflects the strength and diversity of Pivot’s distributed solar portfolio, and we’re proud to support the company through its next stage of growth.”

About Pivot Energy
Founded in 2009, Pivot Energy is a leading national renewable energy provider and independent power producer that develops, owns, and operates solar and energy storage projects. Pivot delivers renewable energy solutions that strengthen local economies, create jobs, and provide affordable, reliable power for businesses and communities across the U.S. As a Certified B Corporation, Pivot combines purpose and performance to ensure every project generates meaningful economic and social value. Pivot is an ECP portfolio company. Learn more at pivotenergy.net.

About First Citizens Bank
First Citizens Bank helps personal, business, commercial and wealth clients build financial strength that lasts. Headquartered in Raleigh, N.C., First Citizens has built a unique legacy of strength, stability and long-term thinking that has spanned generations. First Citizens offers an array of general banking services, including a network of more than 500 branches and offices nationwide; commercial banking expertise delivering best-in-class lending, leasing, and other financial services coast to coast; innovation banking serving businesses at every stage; and a nationwide direct bank. Parent company First Citizens BancShares, Inc. (NASDAQ: FCNCA) is a top 20 U.S. financial institution with more than $200 billion in assets and a member of the Fortune 500™. Discover more at firstcitizens.com.

SOURCE Pivot Energy

Gallatin AI Announces $50 Million Series A to Accelerate Transformation of Military Logistics

EL SEGUNDO, Calif., Oct. 8, 2026 — Gallatin AI, Inc., an AI-native logistics company transforming sustainment decision-making for the U.S. military, today announced $50 million in Series A financing. The round was backed by new and existing investors, including 8VC, Silent Ventures, and others.

“I’m grateful to our early partners across the military logistics community for trusting us with some of the world’s most complex sustainment challenges,” said Woody Glier, Gallatin’s CEO. “This Series A is an important milestone. It gives us the resources to double down on what’s working in the field, accelerate our product roadmap, and scale a capability that builds on the investments in data infrastructure the Pentagon has been making at every echelon. That is how we transform the way joint and allied forces see and sustain themselves. We have the tools and ambition to solve the toughest challenges facing military logistics, and are humbled by the opportunity to keep moving forward.”

Gallatin will use the additional capital to expand its engineering team, accelerate product development, and broaden its suite of AI-enabled sustainment capabilities across the Joint Logistics Enterprise. Navigator, Gallatin’s flagship decision-support platform, connects data and workflows across the force to provide a unified view of readiness while orchestrating critical sustainment processes across vehicle readiness, supply, medical, and other mission-support functions. Navigator is built to transform sustainment decision support from the battlefield to the Pentagon, and is already used by Army and Air Force customers across the tactical, operational, and strategic levels of military planning. Proven in complex fuel, medical, and munitions supply chains, Gallatin’s solutions will expand with the company as it accelerates its permanent presence on four continents.

“Many on our team have lived these sustainment challenges firsthand in uniform, and we know the struggle of not having the information or tools needed to do the job,” said Brian Ballard, the company’s Chief Product Officer. “The opportunity in front of us is bigger than building better software. It is making logistics a source of operational advantage, and giving sustainers the ability to make better decisions before constraints become mission problems.”

Gallatin’s Navigator is currently deployed with U.S. military units around the world, supporting joint and combined exercises from Japan to Alaska to Europe. This funding round follows a successful seed financing in 2024, bringing the total amount raised by Gallatin to $70 million.

About Gallatin

Founded in 2024 and backed by 8VC and leading defense and technology investors, Gallatin AI develops capabilities that make the Joint Logistics Enterprise predictive, visible, and accountable, from the point of production to the point of need. Gallatin is headquartered in El Segundo, California, with offices in Washington, D.C., and Austin, Texas. Its flagship platform, Navigator, is deployed with multiple military units and commercial logistics partners, enabling precision sustainment at the speed of relevance.

For Media Inquiries, please contact Garrett Richards at [email protected]

SOURCE Gallatin AI

GreenLight Fund Investments Reach 1.6 Million Individuals and Families Across 15 Cities in a Single Year

71 portfolio organization investments generated $454 million in funding, addressing locally identified needs nationwide

BOSTON, Oct. 8, 2026 — National nonprofit GreenLight Fund’s 2025-2026 Impact Report shows its investments reached 1.6 million individuals and families this past year, generating progress across essential needs, education, career development and financial resiliency.

From July 2025 through June 2026, GreenLight expanded to Dallas, its 15th city, and grew its national portfolio to 71 investments, bringing proven programs into new communities to address locally identified needs.

“This report demonstrates what is possible when we listen to communities, invest in solutions with a track record of results and provide the support needed to help those programs take root and grow,” said GreenLight Fund CEO Ali Knight. “Reaching 1.6 million individuals and families is an important milestone, and what matters most is the measurable change children and families are experiencing in communities across our network.”

GreenLight’s $47.8 million investment in its portfolio organizations helped unlock more than $454 million in follow-on funding–nearly ten dollars for every dollar GreenLight Fund invested.

GreenLight works alongside residents and local leaders to identify needs, then finds evidence-based nonprofit programs to address them and helps launch those solutions with multiyear funding and support.

Some results highlighted in the report:

  • In Cincinnati, 100% of households participating in HomeStart’s Renew Collaborative retained housing.
  • Across Greater Newark, the Twin Cities and the Bay Area, Food Connect distributed more than 2.3 million meals.
  • In Baltimore, 1,400 ParentChild+ home visits helped prepare 100% of participating families for their children’s academic success. 
  • The Bay Area’s Blueprint Schools reached 1,642 students, with 89% reporting increased confidence in math. 
  • Across six cities, workforce development program participants earned wages 2-3x higher the local minimum wage.
  • In Newark, 77% of EMS Corps graduates obtained full-time employment.
  • Detroit’s RxKids distributed $10.7 million to support 4,195 families during pregnancy and their first year postpartum.
  • Philadelphia’s Compass Working Capital participants graduated with average escrow savings of $9,861. 

“These results and more are possible because local expertise and comprehensive due diligence drive every GreenLight investment,” said GreenLight Fund Co-Founder and Board Chair John Simon. “As we continue growing our national network, we remain focused on listening to communities, investing in solutions with demonstrated results and providing on-the-ground support for long-term sustainability.”

Learn more about GreenLight Fund’s impact: greenlightfund.org/report/our-impact/.

CONTACT: [email protected] 

SOURCE GreenLight Fund

Versapay Expands Its AI Investment with a Unified Intelligence Layer Across the Invoice-to-Cash Workflow

Versapay extends AI that’s been earning trust in cash application for years — now built into collections, payments, and ERP connectivity

SAN FRANCISCO, Oct. 8, 2026 — Versapay, a leading platform for business payments and accounts receivable automation, today announced Versapay Intelligence, an expanded AI layer running across its platform, alongside new capabilities within its core accounts receivable platform and deeper ERP-embedded integrations. Together, the updates extend Versapay’s coverage across invoicing, collections, cash application, payments, and ERP connectivity, reinforcing the company’s position at the center of the invoice-to-cash workflow.

AI is not new to Versapay’s platform. The company has applied AI and machine learning within cash application for years — powering remittance matching and machine-learning-based risk segmentation well before AI became a standard feature in invoice-to-cash software. Today’s announcement expands that investment, unifying it into one intelligence layer that runs across the platform rather than a single module. 

“Versapay is applying one intelligence layer across a platform that already unifies invoicing, collections, cash application, payments, and ERP connectivity,” said Carey Kolaja, Chief Executive Officer of Versapay. “That’s our edge: we’ve spent more than 20 years moving invoices and money, so we see the full picture — not just a transaction, but the operational, payment, and relationship signals behind it. That’s what lets us help define where invoice-to-cash is headed, instead of just keeping pace with it.”

Versapay Intelligence: Earning Trust in Stages

Versapay Intelligence is built around a simple premise: AI is only as valuable as it is trusted, and trust is earned incrementally. Rather than introducing autonomous AI as a headline feature, Versapay designed a four-stage framework that gives customers control over how much responsibility AI takes on, and when:

  • Augment — AI supports workflows, surfaces signals, and eliminates manual research, while the customer makes the final call.
  • Assist — AI shapes outcomes, drafts communications, orders queues, and flags risks, while the customer acts from a position of clarity.
  • Action — AI executes across systems within configured boundaries the customer sets.
  • Autonomous — AI coordinates with other agents and closes loops within permission structures the customer has granted.

Within this framework, three Versapay Intelligence capabilities are live: a Versapay Assistant that answers questions like which invoices to focus on today, real-time sentiment scoring that flags at-risk customer conversations, and AI-generated customer summaries covering payment history, overdue balance, credits, and oldest open invoice. Versapay is also now in beta with AI augmented Cash Application, reading remittance details across PDFs, spreadsheets, and scanned images — in dozens of formats — and matching them to open invoices automatically, greatly improving match rates and predictability, with more capabilities on the way.

“We wanted to use AI to augment our customers’ judgment and take work out of the equation,” said Christy Johnson, Chief Product Officer of Versapay.  That’s why we started with an assistant that answers your questions directly and surfaces the buyer signals that could have been missed, an enhanced AI in Cash Application that shows its work. When AI tells you the insight and explains how it got there, it earns the trust to take on more.”

Expanding Collections Within Versapay’s Core AR Platform

Versapay customers wanted more out of collections capabilities: less manual work and the freedom to build their own strategies. Collections, and connecting customers with their buyers transparently, have always been a core differentiator of the platform. Now Versapay is reaching further leveraging the intelligence above by offering: automatic segmentation by risk and behavior, configurable workflows with tailored outreach cadences, and auto-prioritized task lists that put the highest-priority accounts in front of collectors first. A unified communications log and performance dashboards for DSO, aging, and promise-to-pay complete the picture. 

“We were already running our core AR with Versapay, so expanding into Versapay’s new Collections module felt like a natural next step rather than starting over with a new system,” shared Lisa Pillans, Corporate Controller, Essential Cabinetry Group. We’re most excited about smarter segmentation and automation of routine reminder emails, and getting a daily task list that tells our collector exactly who to follow up with and why — including payment promises — so she can spend her time on the accounts that truly need attention.”

Meeting Customers Inside the Systems They Already Run

Customers asked for one more thing: to be met where they already work, inside the systems they run every day. Versapay continues to embed that intelligence directly into those workflows — across ERPs and other financial systems, including NetSuite, Sage Intacct, and Microsoft Dynamics — so teams can put insights into action as they manage invoices, collections, and cash application. Based on feedback these expanded features have just released:

  • Embedded payments for Microsoft Dynamics F&SCM
  • Expanded NetSuite Pay, with Canadian merchant support 
  • Aggregated payment through grouped invoices through Versapay’s customer portal that sync directly back to NetSuite
  • Project-based and multi-currency invoice support for Sage Intacct

Versapay has also been recognized by G2 with “Users Love Us” and “Leader” badges.

About Versapay

Versapay is the platform that rewires AR by removing barriers from collecting and reconciling B2B payments, providing end-to-end cash flow clarity so businesses can manage working capital on their terms. By connecting finance teams, their business systems, customers, and payment activity into a single intelligent ecosystem, Versapay turns money matters into a data-driven advantage. With 10,000 customers and 5M+ companies transacting, Versapay facilitates 120M+ transactions and processes $300B+ in payments volume annually. To learn more about how Versapay eliminates financial friction, visit versapay.com.

SOURCE Versapay